

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

European Journal of Clinical Microbiology & Infectious Diseases

Manuscript No. EJCM-D-20-01026 R1

Brief report

Primary Resistance to Anti-Retroviral drugs of HIV strains in Chad: a retrospective investigation by analysis of frozen Dried Blood Spot samples

1362 Words

Keita A¹, Djimera N², Djarma O², N’Guyen Y^{3,4}, Bourlet T⁵, Andreoletti L^{4*}.

¹Institut National de Recherche en Santé Publique, Bamako, Mali
²Service de Maladies infectieuses, Hôpital Le Bon Samaritain, CHU Walia, N’Djamena, Chad
³Service de Médecine interne, Maladies infectieuses et Immunologie Clinique, Hôpital Robert Debré, CHU Reims, France
⁴Laboratoire de Virologie médicale et moléculaire, Hôpital Robert Debré CHU Reims & EA-4684, Faculté de Médecine, Université Reims Champagne Ardennes, Reims, France
⁵EA 3064, Faculté de Médecine, Université Jean Monnet, Saint-Etienne, France.

* Corresponding author: Tel: +33 326783993; Fax: +33 326784134; E-mail: landreoletti@chu-reims.fr.

1 **Abstract: (98 words)**

2 *Purpose:* No data concerning Anti-Retroviral drugs (ARV) primary resistance mutation rates
3 in Chad are available.

4 *Methods:* We retrospectively analysed frozen-stored dried blood spot samples that were
5 collected from 48 Chadian Human Immunodeficiency Virus (HIV)-1 seropositive patients
6 naïve of ARV.

7 *Results:* HIV-1 protease and reverse transcriptase genes were successfully sequenced for 24
8 (60.0%) of the 40 patients displaying a viral load >1000copies/ml. Seven (29.2%) displayed
9 mutations conferring resistance against one or more classes of ARV.

10 *Conclusion:* We evidenced high levels of primary ARV resistance mutations in Chad,
11 but lower than those observed in patients with failure to first-line ARV.

12

13

14 **Keywords:** HIV; Chad; Non-Nucleoside Reverse Transcriptase Inhibitor; primary resistance.

15

1 **Introduction:**

2 Access to Highly Active Antiretroviral drugs (ARV) has significantly reduced Human
3 Immunodeficiency Virus (HIV) transmission in sub-Saharan African countries which still
4 support the highest burden of the pandemic [1]. However in these countries, access to free
5 but discontinuous first-line antiretroviral regimens consisting almost exclusively of
6 Nucleoside Reverse Transcriptase Inhibitors (NRTI) combined with a Non Nucleoside
7 Reverse Transcriptase Inhibitors (NNRTI) with low genetic barrier to resistance could rapidly
8 lead to the emergence of antiretroviral drugs resistance among ARV-treated patients. In low-
9 income countries of sub-Saharan Africa, monitoring of HIV plasma viral load that is
10 recommended by World Health Organization (WHO) since 2013 and genotyping tests
11 allowing the detection of HIV strains harbouring resistance mutations to antiretroviral drugs
12 are not continuously available. Horizontal or vertical transmission levels of such HIV strains
13 harbouring major resistance mutations to NNRTIs or NRTIs represent a major public health
14 problem and may significantly impact subsequent choices of antiretroviral drugs regimen for
15 newly HIV infected patients in sub-Saharan African countries.

16 Located in Central Africa, Chad had an estimated HIV seroprevalence of 1.3% among
17 the sexually active population (15-49 years) and ranked fifth in terms of HIV mortality rate
18 (71 per 1000) [2,3]. Moreover, Chad is partly bordered by Cameroon, where a wide diversity
19 of HIV strains has been evidenced [4]. Thus, Chadian HIV strains could present a great viral
20 genetic diversity including non M variants of HIV-1, group M non B subtypes or recombinant
21 strains potentially carrying mutations conferring resistance to antiretroviral drugs used as first
22 or second lines of treatment [5,6]. Only two previous investigations reported high rates of
23 viral mutations conferring resistance to antiretroviral drugs in Chadian patients with
24 virological failure [5,6]. To date, no published data concerning ARV primary resistance

1 mutation rates in Chad are available. In the present report, we retrospectively investigated
2 frozen dried blood spot (DBS) samples from HIV-1 Chadian patients who were naïve of ARV.

3

4 **Patients and methods**

5 From August to November 2012, 48 successive newly HIV-1 seropositive **adult** patients who
6 were naïve of any ARV treatment (30 F/18 M, median age 32years [18-52]) and who were
7 attending to the chronic diseases centre of the hospital “le Bon Samaritain” (N’Djamena,
8 Chad) were enrolled in the present investigation. **World Health Organization HIV disease**
9 **Clinical stage has been defined elsewhere [7].** Median Lymphocytes T-CD4 cells count
10 performed on FACS® count system was **273** cells per mm³ [13 - 1049] for these 48 patients.
11 An oral informed consent for medical research investigations was obtained from each study
12 patient **and if needed from** their relative family members. **This study was approved by local**
13 **ethics committee.** For each patient, blood samples were collected before ARV and sent abroad
14 (“Université” Jean Monnet, Saint-Etienne, and “Université” Reims Champagne Ardennes,
15 France) as dried blood spots (DBS) **after approximately one month of storage at room**
16 **temperature** [8,9]. Each DBS sample was then stored at -80°C until performing HIV-RNA
17 viral load and genotyping assays in France according to previously described protocols [8,9].
18 **Protease gene and reverse transcriptase gene region were fully covered by sequencing**
19 **analysis and obtained sequences were compared against referenced subtype B HBX-2 strain**
20 **(Genbank accession number: K03455.1). All of our HIV-1 sequences were submitted to the**
21 **Genbank and obtained an original accession number (Table 1).** Concerning drug resistance
22 mutations, interpretation of sequencing results was performed according to the French
23 National Agency for AIDS Research resistance algorithm [10]. HIV-1 subtypes were
24 established using the Stanford HIV database **and Sierra version 1.1 HIVdb 8.1.1** [11].
25 **Quantitative variables were compared using the Mann Whitney U-test and qualitative**

1 variables were compared using Pearson's Chi-square test. Statistical analyses were performed
2 using Stat view 5.0 software (SAS institute).

3 **Results**

4 Following RNA extraction from DBS [8], median HIV-1 viral load was estimated to
5 4.72 log copies/ml [3.24- 5.95] for 40 (83.3%) out of the 48 study patients with a detected
6 viral load upper than 1000 HIV-RNA copies per ml. HIV-1 protease and reverse transcriptase
7 genes were successfully amplified and sequenced for only 24 (60.0%) of the 40 patients with
8 a detectable viral load (Table 1). Median HIV-1 viral load and median CD4 cells counts were
9 respectively statistically higher and lower in patients who had successful sequences than in
10 those that did not (Table 2).

11
12 Interestingly, 7 (29.2%) of the 24 successfully sequenced DBS samples exhibited
13 referenced nucleotide mutations conferring HIV-1-resistance against at least one antiretroviral
14 drug. The most frequently detected mutation was the V106I (20.8%) described as a natural
15 polymorphism in HIV-1 non-B subtypes and conferring resistance to etravirine when it is
16 associated to at least one other mutation, according to French National Agency for AIDS
17 Research resistance algorithm [9]. The K103N mutation that confers complete resistance to
18 efavirenz and nevirapine was found in 2 subjects (8.3%) out of the 24. One K65E and one
19 V179D were also detected in two distinct individuals conferring resistance to tenofovir and
20 rilpivirine, respectively. The L90M major protease inhibitor resistance mutation was found in
21 one patient (4.1%). Polymorphic mutations (L10I, G16E, K20I, M36I, I62V, V77I, L89M)
22 were evidenced in 21 sequences (87.5%). HIV-1 protease sequences predicting phenotypic
23 resistance to saquinavir and a combined resistance to nelfinavir, indinavir and atazanavir were
24 evidenced in 3 patients (12.5%).

1 The most prevalent HIV-1 subtype was Circulating Recombinant Form (CRF)
2 CRF11_CPX subtype and was identified in 7 of the 24 samples (29,2%). Others previously
3 described HIV recombinant forms **accounted** for 8 out of the 24 samples (33.3%) (Table 1).

4 All patients were treated by NRTI plus first generation NNRTI (such as efavirenz or
5 nevirapine). Among these 24 patients, 4 died (16.6%) (None among those with mutations
6 leading to resistance or possible resistance to NNRTI), and 14 (58.3%) were lost to follow-up
7 which is consistent with the high attrition rates previously observed in Chad [12].

8 9 **Discussion**

10 In the present report we retrospectively analysed frozen-stored DBS sampled from a
11 series of HIV-1 seropositive patients who were naïve of Highly Active Antiretroviral drugs
12 (ARV) and were living in Chad (Ndjamena), 2012. All of these patients were newly HIV-1-
13 diagnosed and were sampled before initiation of ARV consisting of NRTI and NNRTI
14 combination. We evidenced a CRF11_CPX HIV subtype predominance in accordance with a
15 previously published investigation on Chadian HIV-1 infected patients [5]. Because this
16 previous study focused only patients with detectable viral loads after 6 months of ARV, the
17 reported rates of mutations conferring resistance to at least one antiretroviral drug was high
18 and estimated to 64% [5]. In 2018 Keita et al. observed in plasma samples from newly HIV-
19 diagnosed Malian patients a significant increase of the ARV primary resistance mutation rates
20 evolving from 7.8% in 2010 to 17.5% in 2014, especially mutations conferring resistance to
21 NNRTI like K103N mutation or other natural polymorphic mutations conferring resistance or
22 potential resistance to etravirine, another NNRTI drug not yet currently used in Mali [8]. In
23 the present retrospective monocentric study including a limited series of patients, we showed
24 for the first time high rates of similar ARV primary resistance mutations (29.2%) in Chad,

1 whose levels were lower than those previously observed in Chadian patients (36-64%)
2 displaying a failure to first-line ARV regimen [5,6].

3

4 Our HIV genotyping results could be due to the combined presence of viral RNA and
5 DNA in DBS and the detection of archived mutations currently not detectable by classical
6 genotypic test on plasma RNA. It has been shown that high levels of HIV-1 DNA can induce
7 falsely positive results for the detection of HIV-RNA resistance mutations in about 35% of
8 cases on DBS [13]. However, **even if genotyping assays efficiency declined after DBS storage**
9 **at room temperature [14]**, the use of DBS offers the advantage of a stable and easy to be
10 transported samples with a minimal biohazard risk. Moreover, sending collected blood
11 samples abroad as DBS for further genotyping analysis could be the most reliable way to
12 monitor resistance to antiretroviral drugs because of recurrent blackouts and material/reagent
13 stockouts in low-income countries such as Chad [5,6]. Samples to send abroad could be
14 randomly selected in case of global monitoring of circulation of strains harbouring resistance
15 or individually selected in suspected virological failure cases. In the absence of available
16 HIV-1 RNA load monitoring for each patient, absence of rise of lymphocyte T-CD4 count
17 under ARV is commonly used as a proxy for virological failure in central Africa. In this
18 situation, first line ARV using NRTI plus NNRTI combination is empirically switched to a
19 second line treatment with Protease Inhibitor without waiting for of HIV RNA load results or
20 genotyping analysis performed abroad.

21 Taking into account the few previous published Sahelian reports and our present
22 original results, we suggest that free-access to new cheap antiretroviral drugs with high
23 genetic barrier to resistance should be prioritized over any implementation strategy of HIV
24 genotyping assays in low-income central Africa countries such as Mali or Chad. Dolutegravir
25 containing regimen could be a good candidate for new first-line ARV regimen in these low-

1 income countries, it could be used in association with rifampin and first line anti-tuberculous
2 agents as well as in pregnant women [15]. Dolutegravir containing regimen is now
3 recommended by WHO [15], but to date this ARV drug is not yet in full free-access for the
4 population of Chad.

5

6

7

8

9

10 **Acknowledgements:** We thank Abbott for its support by providing us HIV genotyping
11 kits. We are indebted to Mrs Veronique Sauron and Audrey Jasserand for excellent technical
12 assistance.

13 **Funding:** this work was supported by grants from INRPS (Bamako Mali) and by local grants
14 from University Champagne Ardenne (URCA, France), University Jean Monnet (St Etienne,
15 France).

16 **Conflicts of interest/Competing interests:** none to declare

17 **Ethics approval:** not required in this non interventional study

18 **Consent to participate:** all patients were informed of the study and gave oral consent for the
19 analysis of their samples abroad.

20

21 **References:**

22 **1.** HIV/AIDS Key facts. <https://www.who.int/news-room/fact-sheets/detail/hiv-aids>

23 **2.** UNAIDS. Prevalence of HIV, total (% of population ages 15-49)

24 https://data.worldbank.org/indicator/SH.DYN.AIDS.ZS?end=2016&name_desc=false&start=

25 [1990&view=chart](https://data.worldbank.org/indicator/SH.DYN.AIDS.ZS?end=2016&name_desc=false&start=1990&view=chart)

- 1 **3.** Granich R, Gupta S, Hersh B et al. Trends in AIDS Deaths, New Infections and ART
2 Coverage in the Top 30 Countries with the Highest AIDS Mortality Burden; 1990-2013.
3 PLoS ONE. 2015;10:e0131353
- 4 **4.** Courtney CR, Agyingi L, Fokou A et al. Monitoring HIV-1 Group M Subtypes in Yaoundé,
5 Cameroon Reveals Broad Genetic Diversity and a Novel CRF02_AG/F2 Infection. AIDS Res
6 Hum Retroviruses. 2016; 32 : 381-5.
- 7 **5.** Koyalta D, Charpentier C, Beassamda J et al. High frequency of antiretroviral drug
8 resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy
9 in N'Djamena, Chad. Clin Infect Dis. 2009; 49 : 155-9.
- 10 **6.** Adawaye C, Fokam J, Kamangu E et al. Virological Response, HIV-1 Drug Resistance
11 Mutations and Genetic Diversity Among Patients on First-Line Antiretroviral Therapy in
12 N'Djamena, Chad: Findings From a Cross-Sectional Study. BMC Res Notes . 2017 ;10:589.
- 13 **7.** World Health Organisation. WHO clinical staging of HIV disease in adults, adolescents
14 and children.
15 https://www.who.int/hiv/pub/guidelines/arv2013/annexes/WHO_CG_annex_1.pdf?ua=1
- 16 **8.** Keita A, Sereme Y, Pillet S et al. Impact of HIV-1 primary drug resistance on the efficacy
17 of a first-line antiretroviral regimen in the blood of newly diagnosed individuals in Bamako,
18 Mali. J Antimicrob Chemother. 2019; 74 : 165-71.
- 19 **9.** Mbida AD, Sosso S, Flori P et al. Measure of viral load by using the Abbott Real-Time
20 HIV-1 assay on dried blood and plasma spot specimens collected in 2 rural dispensaries in
21 Cameroon. J Acquir Immune Defic Syndr. 2009; 52 : 9-16.

- 1 **10.** French National Agency for AIDS Research. Table of rules HIV1.
2 <http://www.hivfrenchresistance.org/>
- 3 **11.** Stanford University HIV Drug Resistance Database. HIV Subtyping program.
4 <http://www.hiv.db.stanford.edu/page/hiv-subtyper/>
- 5 **12.** Djarma O, Nguyen Y, Renois F et al. Continuous free access to HAART could be one of
6 the potential factors impacting on loss to follow-up in HAART-eligible patients living in a
7 resource-limited setting: N'djamena, Chad. *Trans R Soc Trop Med Hyg.* 2014; 108 : 735-8.
- 8 **13.** Zida S, Tuailon E, Barro M et al. Estimation of HIV-1 DNA Level Interfering With
9 Reliability of HIV-1 RNA Quantification Performed on Dried Blood Spots Collected From
10 Successfully Treated Patients. *J Clin Microbiol .* 2016;54:1641-1643.
- 11 **14.** García-Lerma JG, McNulty A, Jennings C, et al. Rapid decline in the efficiency of HIV
12 drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS)
13 stored at 37 degrees C and high humidity. *J Antimicrob Chemother.* 2009;64:33-6.
- 14 **15.** World Health Organisation. Update of recommendations on first- and second-line
15 antiretroviral regimens. <https://www.who.int/hiv/pub/arv/arv-update-2019-policy/en/>
16

1 **Table caption:**

2 **Table 1: Virological data obtained from frozen-stored dried blood spot samples of 24**

3 **Chadian HIV-1 seropositive patients naïve of Highly Active Antiretroviral Drugs (ARV).**

4

Patient number	Viral load (log/mL)	HIV-1 subtype	Protease gene mutations	Reverse transcriptase gene mutations	Drug resistance	Possible Drug resistance	Genbank reference
1	4.57	CRF11_CPX	I62V, V77I				MW250374
2	4.44	B		K65E, V75E, I135V, M164L, I178M		TDF	MW250369
3	3.82	CRF11_CPX	G16E, V77I				MW250377
4	4.71	G		K73EQ, K122P, I142V, K173T, Q174K, D177E, E174D, V292I, D324E, I329V			MW250370
5	4.28	CRF45_CPX	K20I, L24F, M36I, L89M	L74H, V179D, K238N, V179D		RPV, EFV, NVP	MW250372 (P) MW250373 (RT)
6	4.37	A1	L90M, L10I, M36I, L89M		NFV	SQV, IDV, ATV	MW250375
7	4.02	CRF13_CPX	K20I, M36I, V77I, I50N				MW250376
8	5.26	CRF11_CPX	L10I, M36I, V77I, L89M				MW250371
9	4.78	CRF11_CPX	L10I, M36I, V77I, L89M				MW250353
10	3.63	D	K20R, M36I	V106I			MW250354
11	4.61	CRF45_CPX	K20X,				MW250356

			M36I, L89M				
12	5.36	D	K20I, M36I, V77I, L89M	V106I			MW250355
13	4.73	CRF45_CPX	L10I, K20I, M36I, L89M			SQV	MW250357
14	4.99	CRF13_CPX	K20I, M36I, L89M	V106I			MW250358
15	4.97	D	M36I, I62V	V106I			MW250359
16	5.79	D	K20R, M6I	V106I			MW250360
17	5.70	D.G	K20I, M36I, I62V, L89M			SQV	MW250361
18	5.43	G					MW250368
19	5.75	CRF11_CPX	I62V, V77I, L89I				MW250362
20	5.56	CRF02_AG	K20I, M36I, L89M	K103N	EFV, NVP		MW250363
21	5.47	CRF11_CPX	I62V, V77I				MW250364
22	4.38	CRF13_CPX	K20I, M36I, V77I				MW250365
23	5.49	CRF02_AG	K20I, M36I, L63P, L89M				MW250366
24	5.95	CRF11_CPX	I62V, V77I	K103N	EFV, NVP		MW250367

Table 2 : Differences between patients with successfully amplified sequences than those without. * The 8 patients with indetectable viral load were considered as missing data among the viral loads of patients without successfully amplified sequences.

	Patients with successfully amplified sequences (n=24)	Patients without successfully amplified sequences (n=24)	P
Male sex (n%)	11 (45.80)	7 (29.10)	0.23
Median Age [range] (years)	33 [20-45]	30 [18-52]	0.23
Median World Health Organization HIV disease Clinical stage [range]	3 [1-4]	2 [1-4]	0.15
Median CD4 Cells counts [range] (/mm ³)	230 [22-1049]	415 [13-918]	0.01
Median viral load [range] (log copies/ml)	4.87 [3.63-5.95]	4.03 [3.24-4.99]*	0.003